Race Oncology Limited (ASX:RAC) is an Australian pharmaceutical company focused on the development of its key drug, Zantrene, which is currently being studied for pre-clinical and clinical efficacy in several cancer indications. Zantrene is a highly targeted precision oncology agent…
To discuss or comment on this announcement please visit our Investor Hub.
To discuss or comment on this announcement please visit our Investor Hub.
Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race’s June 2022 Quarterly Investor Briefing followed by a Q&A session.
30 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results from our preclinical cardioprotection program in collaboration with researchers from the University of Newcastle (ASX announcement: 28 April 2021). This program aimed at exploring the…
28 June 2022 – Race Oncology Limited (“Race”) is pleased to share the final results from our preclinical melanoma research program in collaboration with the University of Newcastle (ASX announcement: 19 March 2021). This program aimed to explore the use…
